Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

Abstract

The use of immune checkpoint inhibitors (ICIs) has increased exponentially in the past decade, although its progress specifically for breast cancer has been modest. The first U.S. Food and Drug Administration approval for ICI in breast cancer came in 2019, eight years after the first-ever approval of an ICI. At present, current indications for ICIs are relevant only to a subset of patients with triple-negative breast cancer, or those displaying high microsatellite instability or deficiency in the mismatch repair protein pathway. With an increasing understanding of the limitations of using ICIs, which stem from breast cancer being innately poorly immunogenic, as well as the presence of various intrinsic and acquired resistance pathways, ongoing trials are evaluating different combination therapies to overcome these barriers. In this review, we aim to describe the development timeline of ICIs and resistance mechanisms limiting their utility, and summarise the available approaches and ongoing trials relevant to overcoming each resistance mechanism.

Keywords

Immunotherapy / immune checkpoint inhibitors / resistance mechanisms / breast cancer

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Arnold M,Rumgay H.Current and future burden of breast cancer: global statistics for 2020 and 2040.Breast2022;66:15-23 PMCID:PMC9465273

[3] Lin MJ,Lubitz GS.Cancer vaccines: the next immunotherapy frontier.Nat Cancer2022;3:911-26

[4] Tsai HJ.Clinical cancer chemoprevention: from the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine.Taiwan J Obstet Gynecol2015;54:112-5

[5] Anassi E.Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.P T2011;36:197-202 PMCID:PMC3086121

[6] Hodi FS,McDermott DF.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010;363:711-23

[7] Lee JB,Ha SJ.Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy.Immune Netw2022;22:e2 PMCID:PMC8901707

[8] FDA. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel. [Last accessed on 15 Nov 2023]

[9] Tawbi HA,Lipson EJ.Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med2022;386:24-34

[10] Cortes J,Cescon DW.Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.N Engl J Med2022;387:217-26

[11] Schmid P,Pusztai L.Pembrolizumab for early triple-negative breast cancer.N Engl J Med2020;382:810-21

[12] Prasad V,Mailankody S.Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers.JAMA Oncol2018;4:157-8

[13] FDA. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors. [Last accessed on 15 Nov 2023]

[14] Nanda R,Dees EC.Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study.J Clin Oncol2016;34:2460-7 PMCID:PMC6816000

[15] Adams S,Rugo HS.Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Ann Oncol2019;30:397-404

[16] Adams S,Toppmeyer D.Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.Ann Oncol2019;30:405-11

[17] Dirix LY,Jerusalem G.Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study.Breast Cancer Res Treat2018;167:671-86 PMCID:PMC5807460

[18] Emens LA,Eder JP.Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study.JAMA Oncol2019;5:74-82 PMCID:PMC6439773

[19] Winer EP,Im SA.Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.Lancet Oncol2021;22:499-511

[20] Bayraktar S,Okuno S.Immunotherapy in breast cancer.J Carcinog2019;18:2 PMCID:PMC6540776

[21] Rezaei N.Cancer Immunology. 2th ed. Springer Cham; 2021.

[22] Zhang Z,Qin Y.Neoantigen: a new breakthrough in tumor immunotherapy.Front Immunol2021;12:672356 PMCID:PMC8085349

[23] Makhoul I,Alwbari A.Breast cancer immunotherapy: an update.Breast Cancer2018;12:1178223418774802 PMCID:PMC5985550

[24] Zhao J.Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1.Chin Med J2020;133:853-62 PMCID:PMC7147660

[25] Chalmers ZR,Fabrizio D.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med2017;9:34 PMCID:PMC5395719

[26] Barroso-Sousa R,Cohen O.Prevalence and mutational determinants of high tumor mutation burden in breast cancer.Ann Oncol2020;31:387-94

[27] Zhuang W,Chen X.The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene panel.J Cancer2018;9:2302-7 PMCID:PMC6036723

[28] Zitvogel L,Smyth MJ.Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.Immunity2013;39:74-88

[29] Garg AD,Rufo N.Trial watch: immunogenic cell death induction by anticancer chemotherapeutics.Oncoimmunology2017;6:e1386829 PMCID:PMC5706600

[30] Adams S,Hamilton E.Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial.JAMA Oncol2019;5:334-42 PMCID:PMC6439843

[31] Tolaney SM,Kaklamani VG.Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib/II study.Clin Cancer Res2021;27:3061-8

[32] FDA. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. [Last accessed on 15 Nov 2023]

[33] Schmid P,Rugo HS.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.N Engl J Med2018;379:2108-21

[34] Miles D,André F.Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.Ann Oncol2021;32:994-1004

[35] Emens LA,Barrios CH.First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.Ann Oncol2021;32:983-93

[36] Weis LN,Barrios CH.Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?.NPJ Breast Cancer2021;7:120 PMCID:PMC8437983

[37] Andre T,Curigliano G.Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study.JCO2021;39:9

[38] Barker AD,Kelloff GJ,Berry DA.I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.Clin Pharmacol Ther2009;86:97-100

[39] Nanda R,Yau C.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.JAMA Oncol2020;6:676-84

[40] FDA. Updated time and public participation information: February 9, 2021: meeting of the oncologic drugs advisory committee meeting announcement. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-and-public-participation-information-february-9-2021-meeting-oncologic-drugs-advisory. [Last accessed on 15 Nov 2023]

[41] Schmid P,Dent R.Event-free survival with pembrolizumab in early triple-negative breast cancer.N Engl J Med2022;386:556-67

[42] Mittendorf EA,Barrios CH.Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.Lancet2020;396:1090-100

[43] Gianni L,Egle D.Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.Ann Oncol2022;33:534-43

[44] Loibl S,Burchardi N.A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.Ann Oncol2019;30:1279-88

[45] Loibl S,Huober JB.Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).JCO2021;39:506

[46] Conte PF,Bisagni G.Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: the A-BRAVE trial.JCO2020;38:TPS598

[47] Saji S,Ignatiadis M.ALEXANDRA/IMpassion030: a phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.JCO2021;39:TPS597

[48] Cortés J,Gonçalves A.IMpassion132 phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.Future Oncol2019;15:1951-61

[49] de Melo Gagliato D, Buzaid AC, Perez-Garcia J, Cortes J. Immunotherapy in breast cancer: current practice and clinical challenges.BioDrugs2020;34:611-23

[50] El Bairi K,Blackley E.The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group.NPJ Breast Cancer2021;7:150 PMCID:PMC8636568

[51] Denkert C,Darb-Esfahani S.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.Lancet Oncol2018;19:40-50

[52] Loi S,Piette F.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.J Clin Oncol2013;31:860-7

[53] Ghebeh H,Al-Omair A.The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.Neoplasia2006;8:190-8 PMCID:PMC1578520

[54] Loi S,Gombos A.Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.Lancet Oncol2019;20:371-82

[55] Emens LA,Beresford M.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol2020;21:1283-95

[56] Agostinetto E,Puglisi F.Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives.Cancers2022;14:2136 PMCID:PMC9105460

[57] Yang T,Li D.Immunotherapy for HER-2 positive breast cancer.Front Oncol2023;13:1097983 PMCID:PMC10061112

[58] Goldberg J,Vallius T.The immunology of hormone receptor positive breast cancer.Front Immunol2021;12:674192 PMCID:PMC8202289

[59] Anders C.Understanding and treating triple-negative breast cancer.Oncology2008;22:1233-43. PMCID:PMC2868264

[60] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[61] Sanchez-Vega F,Armenia J.Oncogenic signaling pathways in the cancer genome atlas.Cell2018;173:321-37.e10 PMCID:PMC6070353

[62] Liu C,Xu C.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.Clin Cancer Res2013;19:393-403 PMCID:PMC4120472

[63] Hu-Lieskovan S,Homet Moreno B.Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF^V600E melanoma.Sci Transl Med2015;7:279ra41 PMCID:PMC4765379

[64] Loi S,Beavis PA.RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors.Clin Cancer Res2016;22:1499-509

[65] Brufsky A,Zvirbule Z.Phase II COLET study: atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).JCO2019;37:1013

[66] Ellis H.PI3K inhibitors in breast cancer therapy.Curr Oncol Rep2019;21:110

[67] Kruger DT,Sanders J,Boven E.Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes.APMIS2020;128:298-307 PMCID:PMC7317370

[68] Peng W,Liu C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy.Cancer Discov2016;6:202-16

[69] Voron T,Pernot S.Control of the immune response by pro-angiogenic factors.Front Oncol2014;4:70 PMCID:PMC3980099

[70] Schmid P,Savas P.Abstract CT049: phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC).Cancer Res2019;79:CT049

[71] Schmid P,Im SA.Abstract PD10-03: BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O).Cancer Res2022;82:PD10-03

[72] MacDonald BT,He X.Wnt/β-catenin signaling: components, mechanisms, and diseases.Dev Cell2009;17:9-26

[73] Hanna A.Breast cancer resistance mechanisms: challenges to immunotherapy.Breast Cancer Res Treat2021;190:5-17

[74] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature2015;523:231-5

[75] Castagnoli L,Cordoba-Romero SL.WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.Oncogene2019;38:4047-60

[76] Platanias LC.Mechanisms of type-I- and type-II-interferon-mediated signalling.Nat Rev Immunol2005;5:375-86

[77] Kotredes KP.Interferons as inducers of apoptosis in malignant cells.J Interferon Cytokine Res2013;33:162-70

[78] Zaretsky JM,Shin DS.Mutations associated with acquired resistance to PD-1 blockade in melanoma.N Engl J Med2016;375:819-29

[79] Gao J,Zhao H.Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy.Cell2016;167:397-404.e9

[80] Bourré L. Targeting tumor-associated antigens and tumor-specific antigens. Crown Bioscience. Available from: https://blog.crownbio.com/targeting-tumor-associated-antigens-and-tumor-specific-antigens. [Last accessed on 15 Nov 2023]

[81] Zou X,Ke H.Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer.Front Immunol2021;12:689076

[82] Ma W,Li T.Cancer neoantigens as potential targets for immunotherapy.Clin Exp Metastasis2022;39:51-60

[83] Schumacher TN,Kvistborg P.Cancer neoantigens.Annu Rev Immunol2019;37:173-200

[84] Gerber HP,Loganzo F.Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?.Biochem Pharmacol2016;102:1-6

[85] Ferraro E,Modi S.Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.Breast Cancer Res2021;23:84

[86] Hurvitz SA,Chung WP.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.Lancet2023;401:105-17

[87] Modi S,Yamashita T.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N Engl J Med2022;387:9-20

[88] Bardia A,Tolaney SM.Sacituzumab govitecan in metastatic triple-negative breast cancer.N Engl J Med2021;384:1529-41

[89] Rugo HS,Marmé F.Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.Lancet2023;402:1423-33

[90] Schmid P,Armstrong A.BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC) - Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).J Clin Oncol2021;39:1023

[91] Schmid P,Wysocki PJ.166MO datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study.Ann Oncol2022;33:S199

[92] Franzese O.Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints.Cancers2022;14:5633

[93] Peyraud F.Combined PARP inhibition and immune checkpoint therapy in solid tumors.Cancers2020;12:1502

[94] Pantelidou C,De Oliveria Taveira M.PARP inhibitor efficacy depends on CD8⁺ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer.Cancer Discov2019;9:722-37

[95] Ding L,Xu X.PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3.Cancer Immunol Res2019;7:136-49

[96] Vinayak S,Schwartzberg L.Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.JAMA Oncol2019;5:1132-40

[97] Domchek SM,Im SA.Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Lancet Oncol2020;21:1155-64

[98] Sammons SL,Im YH. DORA: a phase II, multicenter, international study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (TNBC). Available from: https://www.tempus.com/wp-content/uploads/2022/12/Sammons_DORA_Poster_SABCS2022-.pdf. [Last accessed on 15 Nov 2023]

[99] Yap TA,Dvorkin M.Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial.JAMA Oncol2023;9:40-50

[100] Schram AM,Arrowsmith E.Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial.JAMA Oncol2023;9:29-39

[101] Zhang Q,Tong Z.A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.BMC Med2022;20:321

[102] Vitale M,Rodella L.HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.Cancer Res1998;58:737-42

[103] Henle AM,Puglisi-Knutson D,Knutson KL.Downregulation of TAP1 and TAP2 in early stage breast cancer.PLoS One2017;12:e0187323

[104] Pedersen MH,Beck HC,Ditzel HJ.Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.Oncoimmunology2017;6:e1305531

[105] Garrido MA,Zinchenko S.HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.Immunogenetics2018;70:647-59

[106] Nomura T,Zhau HE,Mimata H.β2-microglobulin-mediated signaling as a target for cancer therapy.Anticancer Agents Med Chem2014;14:343-52

[107] Luo N,Gonzalez-Ericsson PI.DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.Nat Commun2018;9:248

[108] Fares CM,Drake CG,Hu-Lieskovan S.Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?.Am Soc Clin Oncol Educ Book2019;39:147-64

[109] Viehl CT,Liyanage UK.Depletion of CD4⁺CD25⁺ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.Ann Surg Oncol2006;13:1252-8

[110] Simpson TR,Montalvo-Ortiz W.Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.J Exp Med2013;210:1695-710

[111] Meyer C,Costa-Nunes CM.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Cancer Immunol Immunother2014;63:247-57

[112] Kaneda MM,Ralainirina N.PI3Kγ is a molecular switch that controls immune suppression.Nature2016;539:437-42

[113] De Henau O,Winkler D.Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.Nature2016;539:443-7

[114] Chanmee T,Konno K.Tumor-associated macrophages as major players in the tumor microenvironment.Cancers2014;6:1670-90

[115] Qian BZ,Zhang H.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.Nature2011;475:222-5

[116] Scholl SM,Beuvon F.Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis.J Natl Cancer Inst1994;86:120-6

[117] Zhu Y,Meyer MA.CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Cancer Res2014;74:5057-69

[118] Mok S,Tsui C.Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.Cancer Res2014;74:153-61

[119] Najafi M,Mortezaee K.Contribution of regulatory T cells to cancer: a review.J Cell Physiol2019;234:7983-93

[120] Neel JC,Lebrun JJ.The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis.ISRN Mol Biol2012;2012:381428

[121] Gao Z,Zhang H.The roles of CD73 in cancer.Biomed Res Int2014;2014:460654

[122] Sitkovsky MV,Apasov S.Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A_2A receptors.Annu Rev Immunol2004;22:657-82

[123] Wang L,Zhou T.Ecto-5’-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells.J Cancer Res Clin Oncol2008;134:365-72

[124] Spychala J,Ostapkowicz A,Jin A.Role of estrogen receptor in the regulation of ecto-5’-nucleotidase and adenosine in breast cancer.Clin Cancer Res2004;10:708-17

[125] Stagg J,McLaughlin N.Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.Proc Natl Acad Sci U S A2010;107:1547-52

[126] Koyama S,Li YY.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Nat Commun2016;7:10501

[127] Matsuzaki J,Mhawech-Fauceglia P.Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Proc Natl Acad Sci U S A2010;107:7875-80

[128] Johnston RJ,Hackney J.The immunoreceptor TIGIT regulates antitumor and antiviral CD8⁺ T cell effector function.Cancer Cell2014;26:923-37

[129] Thommen DS,Müller P.Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors.Cancer Immunol Res2015;3:1344-55

[130] Davar D,Eroglu Z. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. In: SITC 2018. p.106-7. Available from: https://higherlogicdownload.s3.amazonaws.com/SITCANCER/7aaf41a8-2b65-4783-b86e-d48d26ce14f8/UploadedImages/Annual_Meeting_2018/Annual_Meeting/Abstracts/Abstract_Book_Edited_11_20.pdf. [Last accessed on 15 Nov 2023]

[131] Ascierto PA,Bhatia S.Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations.Ann Oncol2017;28:v611-2

[132] Rodriguez-Abreu D,Hussein MA.Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).J Clin Oncol2020;38:9503

[133] Nair VS, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.Clin Epigenetics2018;10:78

[134] Hong DS,Calvo A.Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.J Clin Oncol2018;36:3012

[135] Jacobs F,Miggiano C,Zambelli A.Hope and hype around immunotherapy in triple-negative breast cancer.Cancers2023;15:2933

[136] Agostinetto E,Nader-Marta G.Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.Expert Opin Investig Drugs2022;31:567-91

[137] Yap TA,Peng W,Curran MA.Development of immunotherapy combination strategies in cancer.Cancer Discov2021;11:1368-97

[138] Alpuim Costa D,Batista MV.Human microbiota and breast cancer - Is there any relevant link? - A literature review and new horizons toward personalised medicine.Front Microbiol2021;12:584332

[139] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9

[140] Vétizou M,Daillère R.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science2015;350:1079-84

[141] Fernandes MR,Costa RGF,Trinchieri G.Targeting the gut microbiota for cancer therapy.Nat Rev Cancer2022;22:703-22